logo
Found Expands GLP-1 Access With Industry-Leading Formulary and Affordability

Found Expands GLP-1 Access With Industry-Leading Formulary and Affordability

Business Wire14-05-2025

MIAMI--(BUSINESS WIRE)-- Found, the leading specialized weight care telehealth platform developed by obesity specialists, today announced it will offer Wegovy® at $499 per month and Zepbound™ vials ranging from $349 to $699. These offerings are made available by prescribing to the innovative direct-to-consumer options developed by Novo Nordisk and Eli Lilly respectively: NovoCare Pharmacy & LillyDirect Pharmacy Solutions. This expansion creates one of the most comprehensive medication formularies in weight care telehealth, with Found clinicians now able to prescribe from more than 15 different medications to deliver personalized care at any budget.
"Making these innovative treatments from Novo Nordisk and Eli Lilly more accessible and affordable is a significant step forward for our members," said Found Head of Medical Affairs Rekha Kumar, MD, MS.
Found clinicians have been prescribing medications from both Novo Nordisk and Eli Lilly since 2022, building industry-leading expertise in how to maximize their effectiveness for sustainable results. To date, this has been primarily for patients using insurance to cover medications. These new offerings are specifically targeted to expand access to those who haven't been able to afford them without insurance coverage. Unlike platforms focused solely on medication access and delivery, Found integrates these treatments within a comprehensive care model validated by peer-reviewed research.
"Since launching in 2019, we've recognized that effective weight care must be as unique as the individuals we serve," said Found CEO Luca Ranaldi. "Our growing formulary addresses the reality that weight care is not one-size-fits-all. By offering multiple medication options and payment solutions, we're building on our long-standing commitment to meet members where they are and provide care tailored to their unique biology, goals, and circumstances."
"Making these innovative treatments from Novo Nordisk and Eli Lilly more accessible and affordable is a significant step forward for our members," said Found Head of Medical Affairs Rekha Kumar, MD, MS. "By bringing together these FDA-approved medications with Found's personalized care approach, we're helping more people achieve their health goals affordably, particularly those who may not have insurance coverage for GLP-1s. This expanded access reinforces our commitment to providing comprehensive, effective treatment options that drive real, lasting results."
Found's industry-leading formulary delivers several benefits:
More Treatment Options: Found clinicians can now prescribe from more than 15 different medications, creating even more personalized treatment plans
More Affordable Care: Wegovy® at $499 monthly (60% off retail) and Zepbound™ starting at $349 makes quality care more accessible
Complete Support: Members receive ongoing care from specialized clinicians, dedicated coaching, and practical tools that address multiple aspects of weight management
Found bridges biology and behavior change through its comprehensive platform, which includes access to one of the industry's most extensive medication formularies, clinical oversight from clinicians trained in obesity medicine, dedicated care team support, one-on-one lifestyle and behavioral coaching, and built-in progress tracking tools.
"Our long-standing history prescribing products from Novo Nordisk and Eli Lilly reflects our shared commitment to responsible care," added Ranaldi. "We're committed to strengthening these relationships to help more people access affordable, effective weight care."
About Found
Found is a physician-designed weight care platform transforming the way society approaches personalized weight management. Founded in 2019, Found provides members with one of the industry's largest medication formularies alongside judgment-free, evidence-based care that combines medication and behavior change support. This comprehensive approach drives lasting results while reducing costs for consumers, employers, and payors. Named one of the best weight loss programs in the United States by Forbes and USA Today, Found is also a member of the Strategies to Overcome and Prevent (STOP) Obesity Alliance. For more information, visit their website.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ProZenith Launches Natural Supplement Formulated for Weight Management Support
ProZenith Launches Natural Supplement Formulated for Weight Management Support

Business Upturn

time2 hours ago

  • Business Upturn

ProZenith Launches Natural Supplement Formulated for Weight Management Support

By GlobeNewswire Published on June 7, 2025, 06:50 IST Aurora, June 06, 2025 (GLOBE NEWSWIRE) — ProZenith recently announced the launch of its new wellness supplement developed to assist individuals in maintaining energy, focus, and mindful appetite awareness as part of a balanced and active lifestyle. Manufactured in the United States in a facility that is FDA-registered and GMP-certified, the product is now available through official online channels. ProZenith is intended for individuals pursuing support for general weight management and overall well-being. Its formulation includes select ingredients chosen to align with healthy routines and support individuals seeking help managing non-hunger-related snacking behaviors. Each purchase of ProZenith is covered by a 60-day refund policy, reflecting the company's customer-first return assurance framework. All ProZenith supplements are manufactured without genetically modified ingredients and adhere to U.S. quality standards. Production takes place in an FDA-registered facility that complies with current Good Manufacturing Practices (cGMP). ProZenith is currently available through the company's official online platform at with multiple purchase options provided for convenience. About ProZenith ProZenith develops nutritional supplements designed to support individuals on their wellness journeys. The company emphasizes high-quality manufacturing, transparency, and customer satisfaction as it continues to expand its product offerings for health-conscious consumers. For customer support inquiries, contact: [email protected] Disclaimer: This product has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Media Contact: Company: ProZenith ProZenith Address: 19655 E 35th Dr #100, Aurora, CO 80011 19655 E 35th Dr #100, Aurora, CO 80011 Email: [email protected] [email protected] Order Phone Support: (925) 217-7353 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.

Lilly's Obesity Drug Sales Rise 60% in India Amid Rising Demand
Lilly's Obesity Drug Sales Rise 60% in India Amid Rising Demand

Bloomberg

time2 hours ago

  • Bloomberg

Lilly's Obesity Drug Sales Rise 60% in India Amid Rising Demand

Eli Lilly & Co. increased sales of weight-loss and diabetes drug Mounjaro 60% in India in May from April in its second full month of being on offer in the South Asian country, which has the world's third-highest number of obese people. The US drugmaker sold 126 million rupees ($1.5 million) worth of the injections last month, according to market analysis firm Pharmarack Technologies. Sales of its 5 mg version more than doubled to about 75 million rupees, while revenue from the 2.5 mg shot was 51 million rupees.

Eli Lilly (LLY)'s Target Price Slashed to $960 by TD Cowen, Reiterates Buy Rating
Eli Lilly (LLY)'s Target Price Slashed to $960 by TD Cowen, Reiterates Buy Rating

Yahoo

time3 hours ago

  • Yahoo

Eli Lilly (LLY)'s Target Price Slashed to $960 by TD Cowen, Reiterates Buy Rating

On June 5, TD Cowen analysts trimmed the price target for Eli Lilly and Company (NYSE:LLY) from $1,050 to $960, while reiterating a Buy rating on the stock. This target price adjustment aligns with investors shifting their focus towards the third quarter results of the SURPASS-CVOT trial. TD Cowen's analysis demonstrates that LLY's tirzepatide needs to match a MACE hazard ratio of 0.9 or better to statistically outperform dulaglutide. A scientist in a lab running tests on a variety of biopharmaceuticals. The investment firm hosted a survey of key opinion leaders, where 92% of the participants said they estimate a hazard ratio of 0.85 or better. Despite the positive outlook among survey respondents, investors remain wary about the possibility of attaining superiority over dulaglutide. Analysts also reworked their financial model for Eli Lilly and Company (NYSE:LLY) after the latest company updates and the Q1 2025 results. The 2026 EPS figures have been trimmed to $29.15, down by $0.25. The stock is now trading at a P/E ratio of 62.07, implying strong growth estimates. Eli Lilly and Company (NYSE:LLY) is a major global pharma giant based in Indianapolis that develops and commercializes medicines for diabetes, cancer, obesity, and autoimmune diseases. While we acknowledge the potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store